LitCovid-sentences  

PMC:7195088 / 25893-29724 JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T193 0-379 Sentence denotes Chloroquine, hydroxychloroquine Some proposed mechanisms are the following: increase in the endosomal Ph necessary for the virus/host cell fusion; interference with the glycosylation of cell receptors; immunomodulatory activity • Not available • Comparison of different hydroxychloroquine dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare workers a risk).
T194 380-504 Sentence denotes Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting).
T195 505-702 Sentence denotes Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months).
T196 703-789 Sentence denotes • Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients.
T197 790-841 Sentence denotes Double-blind RCT (NCT04328961, not yet recruiting).
T198 842-910 Sentence denotes Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days).
T199 911-1047 Sentence denotes • Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19.
T200 1048-1097 Sentence denotes Open-label RCT (NCT04332094, not yet recruiting).
T201 1098-1325 Sentence denotes Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19.
T202 1326-1375 Sentence denotes Open-label RCT (NCT04330586, not yet recruiting).
T203 1376-1449 Sentence denotes Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14.
T204 1450-1576 Sentence denotes • Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors.
T205 1577-1628 Sentence denotes Double-blind RCT (NCT04330495, not yet recruiting).
T206 1629-1839 Sentence denotes Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).
T207 1840-1948 Sentence denotes • Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk.
T208 1949-2000 Sentence denotes Double-blind RCT (NCT04328467, not yet recruiting).
T209 2001-2063 Sentence denotes Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks).
T210 2064-2176 Sentence denotes • Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19.
T211 2177-2228 Sentence denotes Double-blind RCT (NCT04328285, not yet recruiting).
T212 2229-2246 Sentence denotes Primary endpoint:
T213 2247-2335 Sentence denotes Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).
T214 2336-2457 Sentence denotes • Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households.
T215 2458-2501 Sentence denotes Double-blind RCT (NCT04308668, recruiting).
T216 2502-2649 Sentence denotes Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14.
T217 2650-2765 Sentence denotes • Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19.
T218 2766-2824 Sentence denotes Open-label adaptive RCT (NCT04321616, not yet recruiting).
T219 2825-2895 Sentence denotes Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).
T220 2896-3007 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19.
T221 3008-3069 Sentence denotes Double-blind, adaptive RCT (NCT04328012, not yet recruiting).
T222 3070-3146 Sentence denotes Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days).
T223 3147-3305 Sentence denotes • Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19.
T224 3306-3355 Sentence denotes Open-label RCT (NCT04332835, not yet recruiting).
T225 3356-3535 Sentence denotes Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28.
T226 3536-3705 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19.
T227 3706-3759 Sentence denotes Double-blind, adaptive RCT (NCT04315948, recruiting).
T228 3760-3831 Sentence denotes Primary endpoint: severity rating on a 7-point ordinal scale at day 15.